Bisphosphonate treatment inhibits the growth of prostate cancer cells.
暂无分享,去创建一个
F. Singer | M V Lee | E M Fong | F R Singer | R S Guenette | R. Guenette | Frederick R. Singer | M. Lee | E. Fong | Margaret Lee | Eva M. Fong
[1] G. Wesolowski,et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[2] J. Berenson,et al. Pharmacokinetics of Pamidronate Disodium in Patients with Cancer with Normal or Impaired Renal Function , 1997, Journal of clinical pharmacology.
[3] T. Yoneda,et al. Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo , 1995, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[4] G. Rodan,et al. Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[5] G. Passeri,et al. Bisphosphonates stimulate formation of osteoblast precursors and mineralized nodules in murine and human bone marrow cultures in vitro and promote early osteoblastogenesis in young and aged mice in vivo. , 1998, Bone.
[6] J A Kanis,et al. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer. , 1995, The Canadian journal of oncology.
[7] E. Pieterman,et al. Farnesyl pyrophosphate synthase is the molecular target of nitrogen-containing bisphosphonates. , 1999, Biochemical and biophysical research communications.
[8] G. Bilder,et al. 1-Hydroxy-3-(methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. , 1996, Arzneimittel-Forschung.
[9] A. Albini,et al. Effect of osteoblast supernatants on cancer cell migration and invasion. , 1995, Cancer letters.
[10] M. Kovacs,et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. , 1996, The New England journal of medicine.
[11] A. Zwinderman,et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. , 1998, Bone.
[12] D. Wallwiener,et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.
[13] M. Gresser,et al. How Does Alendronate Inhibit Protein-tyrosine Phosphatases?* , 1997, The Journal of Biological Chemistry.
[14] M. Rogers,et al. Nitrogen‐Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post‐Translational Prenylation of GTP‐Binding Proteins, Including Ras , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[15] Y. Oiso,et al. Pamidronate treatment in patients with tumor-associated hypercalcemia: pharmacological effects and pharmacokinetics. , 1994, Endocrine journal.
[16] E. Pieterman,et al. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. , 1999, Biochemical and biophysical research communications.
[17] P Delmas,et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. , 2000, Cancer research.
[18] C. Leu,et al. Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[19] A. Lichtenstein,et al. In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates , 1998, Leukemia.
[20] M. Rogers,et al. Heterocycle‐Containing Bisphosphonates Cause Apoptosis and Inhibit Bone Resorption by Preventing Protein Prenylation: Evidence from Structure‐Activity Relationships in J774 Macrophages , 1998, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[21] M. Koutsilieris,et al. Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. , 1997, Anticancer research.
[22] C S Galasko,et al. Mechanisms of lytic and blastic metastatic disease of bone. , 1982, Clinical orthopaedics and related research.
[23] M. Seabra. Membrane association and targeting of prenylated Ras-like GTPases. , 1998, Cellular signalling.
[24] M. Kitajima,et al. Therapeutic efficacy of pamidronate in combination with chemotherapy to bone metastasis of breast cancer in a rat model. , 1996, Surgical oncology.
[25] T. Powles,et al. Clodronate decreases the frequency of skeletal metastases in women with breast cancer. , 1996, Bone.
[26] H. Fleisch,et al. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. , 1996, Endocrinology.
[27] D. Tindall,et al. The effects of growth factors associated with osteoblasts on prostate carcinoma proliferation and chemotaxis: implications for the development of metastatic disease. , 1997, Endocrinology.
[28] H. Vloedgraven,et al. Bisphosphonates inhibit the adhesion of breast cancer cells to bone matrices in vitro. , 1996, The Journal of clinical investigation.
[29] G. Rodan,et al. Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. , 1991, The Journal of clinical investigation.
[30] G. Rodan,et al. Human protein tyrosine phosphatase‐σ: Alternative splicing and inhibition by bisphosphonates , 1996 .
[31] P. Delmas,et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. , 1997, Cancer research.
[32] J. Bonneterre,et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[33] N. Kugai,et al. Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. , 1996, Bone.
[34] S. Leyvraz,et al. Pharmacokinetics of pamidronate in patients with bone metastases. , 1992, Journal of the National Cancer Institute.
[35] J. Mönkkönen,et al. Farnesol and geranylgeraniol prevent activation of caspases by aminobisphosphonates: biochemical evidence for two distinct pharmacological classes of bisphosphonate drugs. , 1999, Molecular pharmacology.
[36] M. Stearns,et al. Effects of alendronate and taxol on PC-3 ML cell bone metastases in SCID mice. , 1996, Invasion & metastasis.
[37] G. Passeri,et al. Bisphosphonates inhibit IL-6 production by human osteoblast-like cells. , 1998, Scandinavian journal of rheumatology.
[38] M. Koutsilieris,et al. Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. , 1998, Urology.
[39] R. Bataille,et al. Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL‐6 and MMP‐1 by the Tumoral Environment , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.
[40] T. Martin,et al. Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. , 1993, The Journal of clinical investigation.
[41] S. Adami. Bisphosphonates in prostate carcinoma , 1997, Cancer.